The following table presents the Company’s current pipeline: | | | | | | | | | | | | Therapeutic Area | Name | Stage | Product Rights | Cardiometabolic | plozasiran (ARO-APOC3) | Phase 3 | Arrowhead | | zodasiran (ARO-ANG3) | Phase 2b | Arrowhead | | olpasiran | Phase 3 | Amgen | Pulmonary | ARO-RAGE | Phase 1/2a | Arrowhead | | ARO-MUC5AC | Phase 1/2a | Arrowhead | | ARO-MMP7 | Phase 1/2a | Arrowhead | Liver | GSK-4532990 | Phase 2b | GSK | | fazirsiran | Phase 3 | Takeda and Arrowhead | | JNJ-3989 | Phase 2 | GSK | | ARO-C3 | Phase 1/2a | Arrowhead | | ARO-PNPLA3 | Phase 1 | Arrowhead | | ARO-CFB | Phase 1/2a | Arrowhead | Muscle | ARO-DUX4 | Phase 1/2a | Arrowhead | | ARO-DM1 | Phase 1/2a | Arrowhead | Central Nervous System (CNS) | Various | Pre-Clinical | Arrowhead |
|